Back
HFA Premium Access

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment
Topic: Pharmacotherapy
Speaker: Doctor D. Lavall (Leipzig, DE)
Event: Heart Failure 2024

Congress Presentation

Add to my library

Like

About the speaker

Doctor Daniel Lavall

University Hospital Leipzig, Leipzig (Germany)
0 follower

6 more presentations in this session

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction

Speaker: Doctor S. Yun Viladomat (Hospitalet De Llobregat, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy

Speaker: Professor R. Barriales-Villa (Coruna, A, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis

Speaker: Doctor A. Ioannou (Greater London, GB)

Access
Abstract
Slides
Video
Like
Thumbnail

Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Speaker: Miss A. Achten (Maastricht, NL)

Access
Abstract
Slides
Video
Like
Thumbnail

Cardiac manifestations as precursors to ATTR amyloidosis diagnosis: results from the multi-country OverTTuRe study

Speaker: Doctor K. Jarbrink (Gothenburg, SE)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Speakers: Doctor D. Lavall, Doctor S. Yun Viladomat, Professor R. Barriales-Villa, Doctor A. Ioannou, Miss A. Achten...
Access
Video
Like
Thumbnail

About the event

Image

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources